DE-CSC
7.3.2019 15:02:12 CET | Business Wire | Press release
CSC joins the U.S. Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency, the UK National Cyber Security Centre, and other leading security organizations—including Cisco® Talos, FireEye® , and Akamai—in alerting corporations and the public to the recent widespread, state-sponsored domain name system (DNS) hijacking attacks. The targets of these recent attacks include government, corporate, telecommunication, and infrastructure entities resulting in website and email redirection to collect sensitive information. We urge companies to stay vigilant and employ security protocols to reduce exposure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190307005082/en/
“DNS attacks can lead to criminals redirecting web traffic away from a legitimate site to a rogue site, putting customers and companies at great risk,” says Mark Flegg, product director for Security Services at CSC. “The recent attacks are complex and vicious, exploiting weaknesses in DNS infrastructure that many companies set up once, then neglect. We strongly advise clients to use the tools and recommendations available to get their digital infrastructure secure.”
In response to DNS hijacking risk and other cyber crime, CSC introduced CSC Security CenterSM in 2018. It’s an online interface powered by advanced proprietary algorithms designed to expose security blind spots across domain names, DNS, and digital certificates that make vital online brand assets susceptible to DNS hijacking, phishing, and distributed denial of service attacks.
“Domain and DNS hijacking are not new security threats, which is why we developed CSC Security Center and are encouraged that hundreds of the world's largest companies are using it to help protect these critical online elements that enable them to operate,” says CSC Digital Brand Services General Manager Mark Calandra. “The sophistication and impact of the recent wave of attacks serves as a wakeup call that effectively managing domain names, DNS, and digital certificates needs to be a critical component for enhancing the security posture of any company with an online presence.”
CSC Security Center proactively identifies business-critical domains, and monitors them continually to ensure they’re protected. This includes checking for registry- and registrar-level locks that prevent unauthorized changes, reviewing user permissions, and verifying that security-focused, enterprise-class DNS hosting and digital certificates are implemented.
“The new CSC Security Center was a welcome surprise,” says Altan Changezi, lead infrastructure architect at Manulife. “It very quickly allows me to see—at a high level—our overall digital asset configuration at CSC. This includes the status of our most vital domains, as well as the number of users with privileged access to our CSC-managed web portals. The tool allows us to make proactive decisions to take control of our assets, as well as secure our accounts.”
The constant identification and monitoring of vital domains alerting companies to security blind spots allows them to take quick action to reduce real-world online threats to their web presence, customer data, and business-critical functions.
“CSC Security Center has shown us where we needed to consolidate providers, update our permissions and security protocols to be consistent with the importance of the website, and much more,” says John Howell, IT operations manager at Football Federation Australia. “The interface is user friendly and alerts us to where we need to keep watch or increase security. I’ve never seen anything like it before, and knowing I can chat with my CSC rep about any of the security blind spots that are revealed—and get protected right away—gives us peace of mind that our data and customers are protected.”
CSC Security Center helps clients reduce exposure to cyber crime by providing them a single view into all risk areas.
About CSC
CSC helps businesses thrive online. We help effectively manage, promote, and secure our clients’ valuable brand assets against the threats of the online world. Leading companies around the world choose us to be their trusted partner, including more than 65% of the Interbrand® 100 Best Global Brands. Leveraging state-of-the-art technology, Digital Brand Services delivers outstanding outcomes through our unique account management structure. With our expert, dedicated team, you’ll have a daily point of contact to ensure your brand has the strength it needs to succeed in the 21st century. We help consolidate and secure, monitor and enforce, then optimize and promote your brands to maximize your digital presence, secure your digital intellectual property, and reduce costs. CSC is the world’s leading provider of digital brand services to companies around the globe. Headquartered in Wilmington, Delaware, CSC also operates from offices throughout the U.S., Canada, Europe, and the Asia-Pacific region. Learn more at cscdigitalbrand.services .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005082/en/
Contact:
Laura Crozier Public Relations Manager, USA (302) 693-5401 x. 65526 laura.crozier@cscglobal.com
Marie Le Maitre Global Marketing Manager, EMEA +44 (0)20 75132324 marie.lemaitre@cscglobal.com
Letitia Thian Marketing Manager, APAC +65 6709 0104 x. 80104 letitia.thian@cscglobal.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
